tivator, than with PR-A. In addition, SRC-1 from brain, which was confirmed by mass spectrometry, interacted with ER␣ and ER␤ in the presence of agonist but not when unliganded or in the presence of the selective ER modulator, tamoxifen. Furthermore, SRC-1 from hypothalamus, but not hippocampus, interacted more with ER␣ than ER␤, suggesting distinct expression patterns of other cofactors in these brain regions. These findings suggest that interactions of SRC-1 from brain with PR and ER are dependent on ligand, receptor subtype, and brain region to manifest the pleiotropic functional consequences that underlie steroidregulated behaviors. The present findings reveal distinct contrasts with previous cell culture studies and emphasize the importance of studying receptor-coactivator interactions using biologically relevant tissue. (Endocrinology 149:  5272-5279, 2008) T HE STEROID HORMONES, estradiol and progesterone, exert many of their effects on reproductive behavior and physiology by binding to their respective intracellular receptors in specific brain regions (1) (2) (3) . Intracellular estrogen receptors (ER) exist in two forms, ER␣ and ER␤, which are transcribed from different genes (4 -6) . These subtypes differ in their functions (7) , abilities to bind different ligands (8 -11) , and distribution in brain (12) (13) (14) (15) (16) . In addition, cell culture experiments indicate that ER␣ is a stronger transcriptional activator than ER␤ due to differences in the activation function (AF)-1 region of the amino terminus (17) . In most species, progestin receptors (PR) are expressed in two forms; the full-length PR-B and the truncated PR-A, which are encoded by the same gene but are under the regulation of different promoters (18, 19) . In vitro studies indicate that human PR-B is a stronger transcriptional activator than PR-A (20 -24) , due to an additional AF domain in the N terminus of PR-B (25, 26) . These two PR isoforms appear to have distinct functions in reproductive behavior and physiology (27) (28) (29) (30) .
Nuclear receptor coactivators dramatically enhance the transcriptional activity of steroid receptors in vitro, including ER and PR (31) (32) (33) . In addition to early models of nuclear receptor coactivators functioning as a bridge between receptors and the general transcriptional machinery, nuclear receptor coactivators are thought to contribute to nuclear receptor transcription through a variety of processes, including phosphorylation, methylation, acetylation, and chromatin remodeling (32, 34 -36) . The first steroid receptor coactivator to be cloned was steroid receptor coactivator (SRC)-1 [also known as nuclear receptor coactivator (NCoA)-1] (33), which was later found to be a member of a larger family of p160 proteins that includes SRC-2 (glucocorticoid receptor-interacting protein, transcription intermediary factor, and NCoA-2) (37) and SRC-3 (amplified in breast cancer 1, TRAM-1, p/CIP, activator of thyroid and retinoic acid receptor, and RAC3) (38) . Under most conditions, the p160 family and other coactivators physically interact with steroid receptors, including ER and PR, in the presence of an agonist, but not in the absence of ligand or the presence of an antagonist or selective receptor modulators (33, 39 -44) (but cf. Refs. 45, 46) . It is well established that selective estrogen receptor modulators (SERMs) regulate ER activity in a tissuespecific manner (47) . For example, tamoxifen can block ER action through competitive binding or can activate ER, de-pending on the cellular environment, including the ratio of coactivators and corepressors (48) . Using this same rationale, it has been suggested that RU486 is a selective PR modulator (SPRM) (49, 50) .
A variety of studies have begun to investigate nuclear receptor coactivator function in hormone action in brain. SRC-1 mRNA and protein are expressed at high levels in the rodent hypothalamus, hippocampus, cerebellum, paraventricular nucleus, thalamus, and amygdala (51-57) (for review see Ref. 58) . Moreover, recent work revealed that hypothalamic neurons coexpress ovarian steroid receptors (ER and PR) and SRC-1 (59) . In addition, we and others have found that SRC-1 is important for ER and PR action in brain, including regulation of ER transcriptional activity (55, 60) , hormone-dependent sexual differentiation of the brain (61) , and sexual behavior (55, 60 -64) . Finally, the p160 coactivators appear to function in glucocorticoid receptor action in glial cells (65) .
Whereas cell culture studies indicate that receptor-coactivator interactions occur in a ligand-dependent manner, it is not known whether coactivators from brain physically associate with receptors. Therefore, we tested the hypothesis that SRC-1, from brain regions rich in steroid receptors, physically associates with steroid receptors in a ligand-dependent manner. To test this hypothesis, we developed pull-down assays using recombinant PR and ER subtypes and SRC-1 from female rat hypothalamus and hippocampus. The present findings are in contrast with those of previous cell culture receptor-coactivator interaction studies and reveal the importance of investigating these interactions using biologically relevant brain tissue. In addition, such studies may lead to the discovery of new cofactors that modulate steroid receptor action in brain.
Materials and Methods

Experimental animals
Adult female (175-200 g) Sprague Dawley rats from Charles River Breeding Laboratories, Inc. (Wilmington, MA) were housed singly in a 14-h light, 10-h dark cycle, with lights off at 1100 h. Animals were given food and water ad libitum. Female rats were anesthetized with ketamine/ xylazine cocktail (100 mg ketamine and 18 mg xylazine per 0.75 ml/kg in saline) and ovariectomized. A 1-wk recovery period followed to allow clearing of endogenous hormones. All animals were overdosed with sodium pentobarbitol (89 mg/kg) and chloral hydrate (425 mg/kg) and then decapitated. Hypothalamic and hippocampal (containing a small portion of the cortex dorsal to the Hipp) tissues were dissected out and flash frozen on dry ice. Tissue was then stored at Ϫ80 C. All animal procedures were approved by the Institutional Animal Care and Use Committees of Skidmore College and Wellesley College.
Recombinant glutathione-S-transferase (GST)-and Flag-tagged steroid receptors
Recombinant ER and PR fusion proteins were expressed in Spodoptera frugiperda (Sf9) insect cells by the Tissue Culture CORE Facility of the University of Colorado Cancer Center and the Baculovirus/Monoclonal Antibody Facility of the Baylor College of Medicine as described previously (66, 67) . Briefly, full-length human PR-A or PR-B was fused to a GST tag. Insect cell cultures for PR-GST (viruses kindly provided by David Bain, University of Colorado Health Science Center) were incubated with 200 nm of the PR agonist R5020, 200 nm of the SPRM RU486, or in the absence of PR ligand. Full-length human ER␣ or ER␤ was fused to a Flag tag (viruses kindly provided by Lee Kraus, Cornell University, Ithaca, NY) (67, 68) . Sf9 cell cultures for ER-Flag were incubated with 200 nm estradiol, 200 nm 4-hydroxytamoxifen, or no ligand.
Tissue preparation
Brain tissue from female rats (n ϭ 54) was pooled in groups of three for each sample and homogenized in buffer [10 mm Tris, 10% glycerol, 400 mm NaCl, 1 mm DTT, 1 mm EDTA (pH 7.4)] with protease inhibitors (1:10 dilution, P2714; Sigma, St. Louis, MO). Samples were incubated on ice for 30 min and then centrifuged for 30 min at 4 C at 12,000 rpm, and supernatants were aliquoted and frozen at Ϫ80 C.
PR GST pull-down assay procedure
All procedures were carried out at 4 C. Twenty-five microliters of glutathione Sepharose 4B packed resins (Amersham Biosciences, Uppsala, Sweden) were added to siliconized centrifuged tubes and washed with TG buffer [20 mm Tris-HCl (pH 8.0), plus 10% glycerol] containing 100 mm NaCl (TG ϩ NaCl). The resin was then pretreated with ovalbumin (1 mg/ml; Fisher Scientific, Hampton, NH) for 15 min on an endover-end rotator. After three rinses with TG ϩ NaCl, equal amounts of recombinant human PR-GST in 100 mm salt were added to resins and incubated on a rotator for 1 h. The resins were washed with TG ϩ NaCl. Equal amounts of pooled hypothalamic or hippocampal whole-cell extracts were added to the immobilized PR-GST, or GST alone as a control, and incubated on a rotator for 1 h. Resins were washed with TG ϩ NaCl to eliminate nonspecific binding, and then samples were eluted with 2% sodium dodecyl sulfate sample buffer by boiling samples for 5 min and stored at Ϫ80 C until use.
Samples were analyzed by Western blot as described previously (62) for detection of SRC-1 interactions with PR. Briefly, SRC-1 from brain was probed for using a mouse monoclonal antibody generated against amino acids 477-947 of human SRC-1 (1135-H4, 0.5 g/ml, kindly provided by Dean Edwards, Bert O'Malley, Ming Tsai, and Sergio Oñ ate, Baylor College of Medicine, Houston, TX) (43) or a rabbit polyclonal antibody generated against aa 350 -690 of mouse SRC-1 (M-341, 1:750; Santa Cruz Biotechnology, Santa Cruz, CA). Membranes were incubated in a sheep antimouse secondary (1:6000; Amersham) or a donkey antirabbit secondary (1:10,000; Amersham) antibody. Immunoreactive bands were detected with an enhanced chemiluminescence kit (New England Biolabs, Beverly, MA) and membranes exposed to film (Blue Sensitive x-ray film; Laboratory Products Sales, Rochester, NY). Membranes were stripped for 3 h at 70 C in stripping buffer [2% sodium laurel sulfate, 62.5 mm Tris-HCl, 100 mm 2-mercaptoethanol, H 2 O (pH 6.7)] and then reprobed for PR using a mouse monoclonal antibody that recognizes N-terminal amino acids 165-534 of both PR-A and PR-B (PR 1294, 0.1 g/ml, kindly provided by Dean Edwards). Films were placed on a light box (Fotodyne, New Berlin, WI) and photographed with an Olympus Camedia digital camera (Melville, NY). Images were imported into the NIH Image analysis program (version 1.62, National Institutes of Health, Bethesda, MD) on a Power Macintosh G3 computer (Cupertino, CA) and analyzed for immunoreactive band area as measured by number of pixels, which has been found to be consistent with OD data (62) .
ER Flag-tagged pull-down assay procedure
All steps were conducted at 4 C. Twenty-five microliters of packed anti-Flag M2 affinity gel resin (Sigma) was added to each siliconized centrifuge tube and prewashed three times with Tris-buffered saline and two times with 100 mm glycine HCl [100 mm glycine, water (pH 3.5)]. Resins were next washed three times with wash buffer ϩ NaCl [50 mm Tris-HCl, 100 mm NaCl, 1% glycerol, 50 mm Na fluoride, water (pH ϭ 7.4)] ϩ 0.1% Triton X-100. Equal amounts of recombinant Flag-tagged ER were added to the resin column and rotated on an end-over-end rotator for 1 h. The resins with immobilized ER were washed three times with wash buffer ϩ NaCl. Equal amounts of pooled hypothalamic, or hippocampal, whole-cell extracts were added to the immobilized ER-Flag and incubated on a rotator for 1 h. The resins were washed three times with wash buffer ϩ NaCl to eliminate nonspecific binding, and then samples were eluted with 2% sodium dodecyl sulfate sample buffer as described above and stored at Ϫ80 C.
Samples were analyzed by Western blot, as described above, for detection of SRC-1 interactions with ER. After probing for SRC-1, membranes were stripped and reprobed for Flag-tagged ER␣ and ER␤ using a mouse monoclonal antibody generated against the Flag tag (0.25 g/ml, anti-Flag M2; Sigma) and a horseradish peroxidase-linked sheep antimouse secondary antibody (1:80,000 dilution; Amersham Biosciences).
Mass spectrometry
Rat hypothalamic extracts (approximately 40 mg of tissue per condition) were exposed to immobilized ER␣ in the presence of 200 nm estradiol or no ligand. Eluted samples were resolved in adjacent lanes by SDS-PAGE, and the region of the gel corresponding to SRC-1 was excised, digested with trypsin, and desalted as described previously (69, 70) . The peptide mixture was injected onto a C18 trap and then separated on a reversed phase nano-HPLC column (PicoFrrtTM, 75 m ϫ10 cm; tip inner diameter 15 m) with a linear gradient of 0 -50% mobile phase B (0.1% formic acid-90% acetonitrile) in mobile phase A (0.1% formic acid) over 120 min at 200 nl/min. Liquid chromatography and tandem mass spectrometry experiments were performed with an LTQ linear ion trap mass spectrometer (ThermoFinnigan, San Jose, CA) equipped with a nanospray source; the mass spectrometer was coupled on-line to a ProteomX nano-HPLC system (ThermoFinnigan). The mass spectrometer was operated in the data-dependent mode using Xcalibur software. The most intense seven ions in each MS survey scan were automatically selected for tandem mass spectrometry. This approach allows the detection of individual proteins in the nanogram range and has been used to identify proteins in complexes using immunoaffinity purification as well as low abundance transcription factors such as RelA/p65 nuclear factor-B (69, 70) . The acquired tandem mass spectrometry spectra were searched with SEQUEST algorithm from the SWISSPROT Protein Database on the Bioworks 3.2 platform (ThermoFinnigan).
Statistical analysis
Films from Western blots were analyzed as described previously (62) . Data were analyzed as a ratio of area of SRC-1 immunoreactive band to area of PR-A or PR-B band, or area of ER␣ or ER␤ band. Unless stated otherwise, the area of immunoreactive bands was analyzed using a two-way ANOVA in StatView version 5.0.1 (SAS Institute Inc., Cary, NC) to determine differences between receptor subtypes and ligand conditions. Differences were considered significant at a probability of less than 0.05.
Results
PR interacts with neural SRC-1 in a ligand-dependent and subtype-specific manner
GST pull-down assays were used to investigate whether SRC-1 from brain physically associates with PR-A and PR-B and whether these interactions depend on the ligand condition. SRC-1 from the hippocampus interacted with PR-A in the presence of the agonist R5020 (Fig. 1, lane 2) but not in the absence of ligand (Fig. 1, lane 3) . SRC-1 did not interact with the GST tag bound to resin (Fig. 1, lane 4) or the resin alone (lane 5), indicating that there was no nonspecific binding of SRC-1 to the GST tag or resin alone.
SRC-1 from brain associated with both PR-A and PR-B when bound to agonist (Figs. 2, lanes 2 and 5, and 3) . In dramatic contrast, little to no SRC-1 from the hippocampus (Fig. 2, lanes 4 and 7) or hypothalamus associated with PR-A and PR-B in the absence of ligand or in the presence of the SPRM RU486 [F(5, 32) ϭ 17.08, P Ͻ0.0001; Fig. 3, A and B] . In confirmation of these results using the 1135-H4 monoclonal antibody to human SRC-1, similar findings were observed using the rabbit polyclonal antibody to mouse SRC-1 (data not shown). These findings indicate that SRC-1 from brain interacts with PR in a ligand-dependent manner. Figure 2 reveals lower molecular weight bands labeled with the SRC-1 monoclonal antibody that appear to interact with PR-A and PR-B in a manner that is not dependent on the ligand condition because they are present in all three ligand conditions. However, these same immunoreactive bands were observed using the polyclonal SRC-1 antibody (data not shown), suggesting that these bands are fragments of SRC-1 from brain.
Initial findings suggested that SRC-1 associated more strongly with PR-B than PR-A in the presence of agonist (Fig.  2, lanes 2 and 5) . Indeed, SRC-1 from hippocampus ( Fig. 3A) and hypothalamus ( 
ER associates with SRC-1 from the hypothalamus in a receptor subtype-specific manner
Flag-tagged pull-down assays were used to investigate whether ER␣ and ER␤ physically associate with SRC-1 from brain and whether these interactions occur in a ligand-dependent manner. Hypothalamic SRC-1 interacted with ER in a ligand-dependent manner (Figs. 4 and 5B). Estradiol promoted the interactions of hypothalamic SRC-1 with ER␣ and ER␤ (Figs. 4, lanes 2 and 5, and 5B). In contrast, in the absence of ligand or the presence of the SERM, tamoxifen, ER␣ and ER␤ had little to no association with hypothalamic SRC-1 [F(5, 18) ϭ 28.86, P Ͻ0.0001; Fig. 4 , lanes 3 and 6 and 4 and 7, and Fig. 5B ]. SRC-1 from the hippocampus interacted strongly with both hippocampal ER␣ and ER␤ in the presence of estradiol (Fig. 5A ). In the absence of ligand or the presence of the SERM, tamoxifen [F(5, 24) ϭ 22.10, P Ͻ 0.0001], there was little interaction between hippocampal SRC-1 with either ER␣ or ER␤ (Fig. 5A) . Similar SRC-1 and ER interactions were observed using the polyclonal antibody to SRC-1 (data not shown).
Interestingly, SRC-1 from the hypothalamus physically associated more with ER␣ than with ER␤ in the presence of estradiol (Figs. 4, lanes 2 and 5, and Fig. 5B ). In contrast, we did not observe this differential interaction between SRC-1 from the hippocampus and ER␣ (0.42 Ϯ 0.07) and ER␤ (0.32 Ϯ 0.04; P ϭ 0.24, two-tailed t test) (Fig. 5A) . Taken together, these data suggest that that ER subtypes interact with SRC-1 in a brain region-specific manner.
Mass spectrometry confirms hypothalamic SRC-1 interacts with ER␣
To independently confirm the Western blot data for estradiol-dependent binding of ER to SRC-1 from rat brain, we used an unbiased mass spectrometry approach. Rat hypothalamic extracts were exposed to immobilized ER␣ in the presence of estradiol or no ligand, and eluted samples were resolved by SDS-PAGE. Gel slices corresponding to the putative SRC-1 region of the two lanes were digested with trypsin and peptides analyzed by liquid chromatography and tandem mass spectrometry. Database searching identified an abundant, doubly charged peptide with MHϩ of 1336.65907. Whereas no matches were found in the rat SwissProt database, a search of the far more completely annotated human database matched the amino acid sequence SDISSSSQGVIEK with highly significant scores of XCorr ϭ 3.62 and DeltaCn ϭ 0.45. Furthermore, 18 of 24 of the observed fragment ions matched the predicted fragment ions. This peptide corresponds to amino acids 97-109 of the human nuclear receptor coactivator 1 (EC 2.3.1.48) with gene name of NCoA-1 (SRC-1) and SwissProt accession no. Q15788. It is important to note a match in the rat database was not found because, despite 100% identity of this human peptide with mouse, chicken, pig, and many other species, the rat NCoA-1 sequence is not currently in the SwissProt database. Interestingly, this peptide was found in the slice from the lane eluted from estradiol-bound ER␣ and not in the slice eluted from unliganded ER␣, confirming our findings from the Western blot analysis.
Discussion
To test the hypotheses that SRC-1 from brain physically associates with PR and ER subtypes in a ligand-dependent 3 and 6) or in the presence of the SPRM, RU486 (lanes 4 and 7) . Input (1% of total) of SRC-1 from hippocampal extract is shown in lane 1.
FIG. 3. SRC-1 from the hippocampus
and hypothalamus associates with PR in a ligand-dependent and receptor subtype-specific manner. A, SRC-1 from hippocampal extracts interacted with both PR-A and PR-B in the presence of R5020 but not the absence of ligand or the presence of RU486. *, P Ͻ 0.0001, significantly different from PR-A ϩ R5020; #, P Ͻ 0.01, significantly different from PR-B ϩ R5020, and SRC-1 from hippocampus interacted more with PR-B than PR-A when bound to R5020. **, P Ͻ 0.05, t test. B, Hypothalamic SRC-1 interacts with PR-A and PR-B when bound to R5020, but little to no interactions were detected in the absence of ligand or when receptors were bound to RU486, *, P Ͻ 0.01, significantly different from PR-A ϩ R5020; #, P Ͻ 0.001, significantly different from PR-B ϩ R5020, and SRC-1 from the hypothalamus interacted more with PR-B, than PR-A when bound to R5020; **, P Ͻ 0.05, t test, n ϭ 5-7 per treatment group. manner, we developed pull-down assays with brain tissue from female rats. We found that SRC-1 from hypothalamic or hippocampal extracts interacted with both GST-tagged PR-A and PR-B when bound to the agonist R5020. In contrast, very little to no SRC-1 from brain associated with PR-A or PR-B in the absence of ligand or the presence of the SPRM, RU486. These findings are consistent with previous studies using recombinant SRC-1 and the concept that SRC-1 and PR interactions are agonist dependent (33, 71) . The present findings support our previous work indicating a role for SRC-1 action in the hypothalamus in PR-dependent female sexual behavior (62) and suggest that SRC-1 may contribute to the effects of progestins on memory in the hippocampus (72) .
Interestingly, we found that SRC-1 from hypothalamus or hippocampus interacts more with PR-B than with PR-A in the presence of agonist (Fig. 3) . The present results are in contrast to other pull-down assays using recombinant SRC-1. In one study, full-length recombinant SRC-1 interacted equally with PR-A and PR-B when bound to agonist (43) . In another pull-down study, an SRC-1 fragment interacted with PR-B but not PR-A (71). Taken together, the present findings suggest the importance of using biologically relevant tissue, in contrast to the use of cell lines alone, in these pull-down assays. It may be that other cofactors and proteins, that are present in brain, are important for appropriate SRC-1 and PR interactions.
In vitro studies indicate that human PR-B is a stronger transcriptional activator than PR-A (20, (22) (23) (24) due to the additional AF-3 region of PR-B (25, 26) . It is likely that this additional AF domain in PR-B allows for enhanced recruitment of coactivators, thus augmenting the transcriptional activity of PR-B (24, 25, 73) . Interestingly, a recent study indicated that both PR isoforms are required for the complete expression of female sexual behavior in mice (27) . Whereas it is not known whether PR-B is a stronger transcriptional activator than PR-A in brain, our findings suggest that PR-B is a stronger activator of SRC-1-dependent progesterone signaling pathways in brain than PR-A.
SRC-1 from hypothalamus or hippocampus interacted with ER␣ and ER␤ when bound to estradiol (Figs. 4 and 5) . In contrast, very little to no association of SRC-1 from brain was detected with ER␣ or ER␤ in the absence of ligand or the presence of the SERM, tamoxifen (Figs. 4 and 5) . Our findings are consistent with a variety of studies using cell lines demonstrating that estradiol facilitates the association of SRC-1 with ER, whereas antagonists prevent this association (40, 48, 74, 75) . In contrast to the present findings, under certain 5 . ER recruits SRC-1 from the hypothalamus in a receptor subtype-specific manner. A, In the presence of estradiol, both ER␣ and ER␤ interacted with hippocampal SRC-1, but little to no interactions were detected in the absence of ligand or when receptors were bound to tamoxifen. *, P Ͻ 0.0001, significantly different from ER␣ ϩ estradiol; #, P Ͻ 0.0001, significantly different from ER␤ ϩ estradiol. B, Hypothalamic SRC-1 interacted more strongly with both ER␣ and ER␤ in the presence of estradiol than in the absence of ligand or when receptors were bound to tamoxifen. *, P Ͻ 0.0001, significantly different from ER␣ ϩ estradiol; #, P Ͻ 0.01, significantly different from ER␤ ϩ estradiol, and SRC-1 interacted more with ER␣ than ER␤ when bound to estradiol; **, P Ͻ 0.05, t test, n ϭ 4 -5 per treatment group. phosphorylation conditions, cell culture studies suggest that both ER␣ and ER␤ can recruit coactivators to AF-1 in the absence of ligand (45, 46) . Whereas we detected little to no interactions between receptor and SRC-1 from brain in the absence of ligand, it will be important to investigate whether physiologically relevant events that modulate ligand-independent activation impact on receptor-coactivator interactions in brain. Furthermore, under the present experimental conditions, it appears that the selective receptor modulators, tamoxifen and RU486, function as antagonists to prevent receptor-coactivator interactions.
In the present studies, SRC-1 from the hippocampus appears to interact equally with ER␣ and ER␤ (Fig. 5A) . Association of SRC-1 with ligand-bound ER␣ and ER␤ in the hippocampus may be an integral component of estrogen's effects on cognition and memory (76, 77) . Interestingly, in contrast to the hippocampus, SRC-1 obtained from hypothalamic extracts interacted more with ER␣ than ER␤ (Figs.  4 and 5B). ER␣, and to a lesser extent ER␤, are expressed in the hypothalamus (12) (13) (14) (15) (16) . In the hypothalamus, ER␣ is necessary for the full expression of rodent female sexual behavior (78 -82) , whereas ER␤ in this region appears to influence anxiety and the stress response (77, 83) . These different functions of the ER subtypes in brain may be explained in part by the different transcriptional abilities of these receptors. The amino terminus is shorter in ER␤ than ER␣, which may account for the lower transcriptional activity of ER␤ observed in particular cell lines (17) . These differences in transcriptional abilities between ER␣ and ER␤ may be attributed to differential recruitment of coactivators, or differences in the ability of the same coactivator to facilitate transcription of the ER subtypes (84) . Whereas some studies using recombinant SRC-1 are consistent with our findings that SRC-1 interacts more with ER␣ than with ER␤ (84), other findings suggest that SRC-1 associates equally with each ER subtype (74, 85) . Whereas these later findings are consistent with our results using SRC-1 from hippocampus, we observed that SRC-1 from hypothalamus interacted more with ER␣ than ER␤.
These data suggest that ER␣ is a more efficient transcriptional activator of SRC-1-dependent signaling pathways in the hypothalamus than ER␤. In support, previous findings from our laboratory indicate that SRC-1 function in the hypothalamus is important for maximal expression of ER-mediated female sexual behavior (62) , which appears to be ER␣ dependent (78, 79) . These differential interactions of SRC-1 from hypothalamus or hippocampus with the ER and PR subtypes suggest that these brain regions have distinct expression patterns of cofactors involved in these important protein-protein interactions. In addition, it is possible that SRC-1 undergoes differential phosphorylation in these two brain regions, leading to distinct patterns of interaction with receptors. Future experiments will need to apply mass spectrometry analysis to determine whether, in a brain regionspecific manner, different cofactors are present in the receptor-coactivator complex and/or whether SRC-1 undergoes differential phosphorylation.
These pull-down assays allow us to directly address the differential interactions of SRC-1 with the PR and ER subtypes. In addition, this approach allows the efficient detection of protein-protein interactions and the application of mass spectrometry. However, one must be careful in interpreting the results from these assays, given that nonspecific interactions can occur. In the present studies, little to no interactions were detected between SRC-1 from brain and the fusion protein tags alone (GST or Flag tags) or the resins only (Fig. 1) , suggesting there were no significant nonspecific interactions between SRC-1 and fusion tags or resins. Moreover, Western blot analysis and mass spectrometry revealed that SRC-1 interacted with receptor when bound to agonist but not when bound to antagonist or unliganded, suggesting these coactivator-receptor interactions were specific. It should be noted that human ER and PR proteins were used to investigate interactions with SRC-1 protein from rat brain. It is possible that SRC-1 from rat brain may interact differently with human ER and PR, compared with rat receptor. However, the human PR ligand binding domain (LBD), the receptor region most critical for SRC-1 interactions (32, 86) , has a high degree of protein sequence homology (92%) with the rat PR LBD (BLAST) (18, 87) . Furthermore, the LBDs of human ER␣ and ER␤ are 89 and 90% identical in protein sequences to the LBDs of rat ER␣ and ER␤, respectively (88) . However, given that discrete differences in protein structure can lead to differences in protein interactions, it will be important to investigate endogenous interactions between SRC-1 and steroid receptors in brain using coimmunoprecipitation assays in future studies. Nevertheless, the high degree of homology between the rat and human LBDs of PR and ER, taken together with the ligand-dependent nature of the interactions in the present studies, suggest that our findings provide important insights into the physical associations of SRC-1 from brain and these receptors.
In conclusion, the present data indicate that SRC-1 from hypothalamus and hippocampus physically associate with ER and PR in a ligand-dependent manner. These findings extend our previous studies showing that SRC-1 is expressed in ER and PR containing cells in brain regions important for reproductive behavior (59) . In addition, these protein-protein interaction studies provide further support for work from our laboratory and others that reveal an important role for SRC-1 in ER and PR action in brain (55, 60 -63) . Moreover, the present studies reveal that SRC-1 from brain interacts differentially with ER and PR subtypes in a brain regionspecific manner. Understanding how nuclear receptor coactivators function with various steroid receptors, and their subtypes, is critical to understanding how hormones act in different brain regions to profoundly influence physiology and behavior. Ultimately, investigation of these receptorcoactivator interactions using brain tissue may allow the identification of novel cofactors involved in the steroid receptor complex in brain.
